There were already randomized controlled trials supporting the therapeutic value of antagonistic anti-CD40 monoclonal antibodies in autoimmune diseases such as rheumatoid arthritis and graves hyperthyroidism (Espié et al., 2020; Kahaly et al., 2020). Here, CD40 is linked to rheumatoid arthritis.